|
|
|
| home > white papers > Biosimilars In Emerging Markets: Is It A Level Playing Field? - PRA Health Sciences (PRA) |
|
|
 WHITE PAPERS |
|
PRA Health Sciences (PRA)
|
|
Biosimilars In Emerging Markets: Is It A Level Playing Field?
|
|
Governments, healthcare payers, and social and health reforms, combined
with the increased incidence of conditions such as cancer and diabetes
are paving the way for increased uptake of biologic medicines in
emerging markets. However, expensive biologic medicines can be
prohibitive to many patients, creating a high level of unmet clinical
need. At its best, the global expansion of biosimilars can mean a robust
and steady supply of existing and new drugs reaching far-flung patient
populations, but localized biosimilar drug developments, especially in
China and India, combined with a lack of robust pharmacovigilance
systems, threaten to derail the industry by putting patient health at
risk.
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Registration Opens for Inaugural HPAPI USA Conference in October
The HPAPI global market is growing at an ever-increasing rate of CAGR at 8.6% that is projected to reach USD $31.56 Billion by 2025, with a significant segment market of HPAPI being oncology ADC which is at a CARG of a staggering 20%. The continual elevation of HPAPI potencies along with toxicity will further drive the needs for more cutting-edge containment solutions and best practices guidelines to ensure workers safety.
More info >> |
|
 |
White Papers |
 |
|
The BioPharmaSpec Approach”: Mass Spectrometry Based Host Cell Protein Identification and Quantitation
BioPharmaSpec
1. Introduction
As part of the development of any biopharmaceutical product, the impurities present must be examined, minimized and where possible characterized (1). These impurities fall into two broad categories: product-related impurities (derived specifically from the drug product itself) and process-related impurities (derived from material associated with the production, processing or purification of the sample). Host cell proteins (HCPs) are process-related impurities that require specific analysis due to the multitude of naturally occurring proteins expressed in the production cell line.
More info >> |
|
 |
Industry Events |
 |
Evolution Summit
4-7 May 2020, The Ritz Carlton, Fort Lauderdale, FL
POSTPONED: NEW DATE TBC
The 22nd Evolution Summit is the premium forum bringing leading drug
development executives and solution providers together. As an
invitation-only event, taking place behind closed doors, the Summit
offers an intimate environment for a focused discussion of key new
drivers shaping drug development.
More info >> |
|
|
|
